Physician profile
Daniel C Clower
NPI 1861483026
$3,673.57
in general payments reported to CMS, 2019-2025
32 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $464 · 2021: $817 · 2022: $539 · 2023: $321 · 2024: $487 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $546.93 | 2020-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $506.14 | 2019-2023 | |
| Abbvie INC. | $464.24 | 2021-2024 | |
| Novo Nordisk INC | $315.93 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $247.33 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $203.23 | 2019-2021 | |
| Mylan Specialty L.P. | $160.73 | 2019-2024 | Yupelri |
| Astrazeneca Pharmaceuticals Lp | $159.99 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.77 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.45 | 2024-2025 | |
| Shield Therapeutics INC | $98.83 | 2023-2025 | Accrufer |
| Pfizer INC. | $95.89 | 2019-2023 | |
| Amgen INC. | $92.15 | 2019-2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $84.20 | 2021-2022 | |
| Allergan, INC. | $42.49 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $42.47 | 2021 | |
| Janssen Pharmaceuticals, INC | $33.97 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $32.59 | 2022-2025 | Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.17 | 2021-2023 | Xifaxan |
| Neurocrine Biosciences, INC. | $27.87 | 2025 | |
| Lundbeck LLC | $25.57 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.93 | 2025 | Caplyta |
| Ultragenyx Pharmaceutical INC. | $24.51 | 2022 | |
| Amarin Pharma, INC. | $22.63 | 2019 | |
| Dexcom, INC. | $19.75 | 2023 | Dexcom G6 Transmitter |
| Insulet Corporation | $17.06 | 2023 | Omnipod |
| Astellas Pharma US INC | $16.63 | 2023 | Myrbetriq |
| Exact Sciences Corporation | $16.03 | 2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $15.53 | 2023 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $15.11 | 2023 | Livalo, Seglentis |
| Phathom Pharmaceuticals, INC. | $14.71 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $13.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Clower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.